A Win For Equillium, Inc.

Fri, Aug 01, 2025 at 07:36 PM

Equillium, Inc. (EQ:NASDAQ) soared at $0.71, a gain of 81.6%. On Fri, Aug 01, 2025, EQ:NASDAQ touched a New 2-Week High of $0.71. From Fri, Jul 18, 2025, the stock recorded 50.00% Up Days and 36.36% Green Days

The stock spiked on Fri, Aug 01, 2025 at $1.36 with a volume of 140M+.

About Equillium, Inc. (EQ:NASDAQ)

Equillium Inc is a biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is EQ001, which is a clinical stage first-in-class monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 plays a central role in effector T cell activity, which drives a number of immuno-inflammatory diseases such as graft versus host disease, asthma, uveitis, colitis, lupus and multiple sclerosis.

Top 10 Gainers:

Ikena Oncology, Inc. (IKNA:NASDAQ), 1152.55%
Hempacco Co., Inc. (HPCO:NASDAQ), 800%
Lobo EV Technologies Ltd. (LOBO:NASDAQ), 118.69%
Performant Healthcare, Inc. (PHLT:NASDAQ), 115.21%
Fundamental Global Inc. (FGF:NASDAQ), 84.22%
Equillium, Inc. (EQ:NASDAQ), 81.59%
Marwynn Holdings, Inc. (MWYN:NASDAQ), 53.33%
EZGO Technologies Ltd. (EZGO:NASDAQ), 51.7%
Tenon Medical, Inc. (TNON:NASDAQ), 45.58%
4D Molecular Therapeutics, Inc. (FDMT:NASDAQ), 42.67%